Iradimed Corporation Reports Record Q3 2025 Revenue of $21.2 M, Raises Full-Year Guidance

Iradimed Corporation reported record revenue of $21.2 million for the third quarter of 2025, a 16% increase from the previous year. The company achieved a GAAP diluted earnings per share (EPS) of $0.43, reflecting an 8% rise, and a non-GAAP diluted EPS of $0.47, up 9% year-over-year. Iradimed raised its full-year revenue guidance to between $82.5 million and $83.5 million and increased its GAAP diluted EPS guidance to $1.68 to $1.72. The company declared a quarterly cash dividend of $0.17 per share, payable on November 25, 2025. Despite some transitional challenges due to moving to a new facility in Orlando, the company maintained a strong gross margin of 78% and reported a record backlog of orders, positioning itself for future growth, including the upcoming limited commercial shipments of its next-generation MRI-compatible IV infusion pump.

https://www.quiverquant.com/news/Iradimed+Corporation+Reports+Record+Q3+2025+Revenue+of+%2421.2+Million+and+Raises+Full-Year+Guidance